Dr. Goy on CAR T-Cell Therapy Updates in Non-Hodgkin Lymphoma

Video

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.

Many of the studies presented at the 2019 ASCO Annual Meeting related to CAR T-cell therapy were trials in progress. However, one study that had data read out included a subset from the ZUMA-1 trial, which demonstrated promising efficacy and safety data in patients older than 65 years with axicabtagene ciloleucel (Yescarta). Moreover, in the TRANSCEND NHL 001 trial, lisocabtagene maraleucel, another CAR T-cell product, also demonstrated benefit in patients with relapsed/refractory mantle cell lymphoma.

In patients with relapsed/refractory central nervous system lymphoma, data also showed that CAR T-cell therapy is feasible and demonstrated preliminary activity.

<<< 2019 ASCO Annual Meeting

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.